Almighty Gwunder Biomedical

W.P.B. Xiqing Su

The world’s first topical biotech health product
Developed over eight years, this innovative biomedical patented formula—W.P.B.—works synergistically with twelve highly concentrated health-promoting botanicals to enhance nature’s self-healing power. Using a proprietary bio-technology oscillation-assisted absorption method, it penetrates to the blood vessels beneath the skin within 0.1 seconds.

Benefits after application:

1. First, eliminates blood impurities


2. Then, boosts blood circulation


3. Finally, supports deep cellular repair



Registered and approved by the U.S. FDA, certified by SGS, and covered by NT$50 million product liability insurance from Nan Shan Life Insurance—ensuring the highest level of product safety and protection for users.

With consistent use, you may experience:

Improved local circulation issues (e.g., cramps) within 10 seconds

Cleansing of blood and cellular activation within 30 seconds

Relief from pain and discomfort within 10 minutes

Long-term support for chronic condition improvement

No hepatic or renal metabolism—placing minimal burden on the body


Recommended use:
Daily circulation maintenance, discomfort relief, cramps, indigestion, and localized blood stasis or bruising.

Amaran Biotechnology, Inc.

Amaran Biotech provides a range of drug development services, from initial process development & optimization, supply chain management, to clinical and commercial cGMP-compliant manufacturing with a comprehensive range of analytical and regulatory support, its CDMO solution includes:
〉AB-801 Vaccine Adjuvant: It has similar application capabilities to the widely used QS-21 adjuvant and is GMP-grade.
〉Drug Product Manufacturing: Taiwan\\\'s first fully automated robotic aseptic filling line, the SA25, provides high-quality, low-waste filling solutions for high-value new drugs.
〉Drug Substance Manufacturing: include ozonation, thiolation, dialysis, bioconjugation (glycoprotein conjugation), column purification of proteins and natural products.
〉Stability Study and Analytical Science Services

American State Offices Association (ASOA)

With the mission of strengthening U.S.–Taiwan relations, the U.S. Pavilion serves as a joint platform for state offices in Taiwan to promote bilateral trade and investment opportunities. It assists Taiwanese companies in investing in the United States and supports U.S. products entering the Taiwan market. The Pavilion also regularly organizes and participates in events related to trade, investment, education, and tourism to further enhance people-to-people and industry connections.

AmLife INTERNATIONAL CO., LTD.

AmLife DeepZleep Amsonic Electric Potential and HyperthermiaTherapeutic Device is a highly efficient home health device that combines advanced Japanese medical technology with natural therapies. Certified by Japan’s Ministry of Health, as well as authorities in Taiwan, Malaysia, and other countries, it provides eight major therapeutic benefits, including relief from headaches, neck and shoulder stiffness, and chronic insomnia. This product integrates electric potential therapy, hyperthermia treatment, and an exclusive patented sound frequency therapy, offering comprehensive health protection that can be easily used at home every day. Users can choose from five smart sleep programs, ranging from wellness and fitness to enhanced blood circulation and deep sleep, with fully automated and simple-to-use operation.

As a market-leading sleep health product, it is widely recognized internationally and has undergone rigorous scientific validation, ensuring long-term durability and safety.

The DeepZleep Electric Potential and Hyperthermia Therapeutic Device is not only an ideal choice for family health care but also an innovative product with both economic benefits and market potential. Helping people \\

ANYONG FRESHMART, INC.

APEX BIOTECHNOLOGY CORP.

Established in Taiwan in 1997, APEXBIO is a leading diagnostic solution provider. Utilizing our know-how and broad intellectual properties in biosensor development and manufacturing, our products are currently sold in more than 80 countries worldwide and are helping healthcare providers and consumers alike to manage conditions including diabetes, anemia, hyperlipidemia, emergency care, and other chronic and acute conditions.

Applied BioCode Taiwan Ltd

17-Plex Gastrointestinal Pathogen Panel (GPP)
17-Plex Respiratory Pathogen Panel (RPP)
BioCode MDx3000 Automated High Throughput Molecular Diagnostic System

APrevent Medical Inc.

APrevent VOIS is specifically designed for medialization thyroplasty procedure for treatment of unilateral vocal fold paralysis and/or glottic insufficiency. The goal is to get optimized results with reduced complications and revision rates. It is the first implant in the market that can be adjusted both intra- and postoperatively. Postoperative implant adjustments make it possible to optimize individual needs without revision surgery.

Arbo3 Inc.

Arbo3 Inc. is revolutionizing air purification with its patented, AI-controlled ozone disinfection system. Tackling poor indoor air quality, Arbo3 delivers medical-grade sterilization by continuously neutralizing pathogens in the air and on surfaces. Unlike HEPA filters or UV-C, Arbo3’s low-dose ozone (<100ppb) offers safe, autonomous, and scalable sanitization for healthcare, transportation, hospitality, and retail. The system features real-time AI-based automation, cloud-managed web-portal, mobile app, and filter-free design for cost efficiency. Certified by SGS Group for efficacy and safety, Arbo3 has demonstrated market traction in Taiwan with deployments in Taiwan Taxi (55688) and the selection for use in a major Taipei hospital.

ARCE Therapeutics.com

ARCE, a global biotech company specialized in developing immune cell & gene engineering technology, announced earlier today that the US FDA has cleared its IND application for ARD103, an autologous CAR-T therapy, for phase 1/2 clinical trials in patients with relapsed/refractory acute myeloid leukemia (r/r AML). ARCE plans to launch its phase 1/2 study and enroll qualified patients by Q1 2025. ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with high transduction, stem cell-like phenotypes and ultra-fast manufacturing in 3-5 days. In addition, FDA has granted Orphan Drug Designation (ODD) to ARD103 for treatment of acute myeloid leukemia (AML). It may be a first-in-class CLL-1 CAR-T therapy. We look forward to administering ARD103 to our first patient within the next few months. We are thrilled that ARCE is well-positioned to achieve a key program milestone.